Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study

Maria Mico', Alessandra Algarotti, MD, Anna Grassi, MD, Chiara Pavoni, Statistician, Francesco Onida, MD, Nicola Mordini, Maria Luisa Ferrari, Federico Lussana, MD PhD, Maria Chiara Finazzi, MD, Daniela Taurino, MD, Chiara Capelli, Martino Introna, MD, Alessandro Rambaldi, MD PhD

Blood (2018) 132 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2018-99-118444

Published: 2018

Journal Articles

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Blood (2018) 132 (Supplement 1): 196.

https://doi.org/10.1182/blood-2018-196

Published: 2018

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Blood (2016) 128 (22): 1160.

https://doi.org/10.1182/blood.V128.22.1160.1160

Published: 2016

Journal Articles

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation

Blood (2016) 128 (22): 3374.

https://doi.org/10.1182/blood.V128.22.3374.3374

Published: 2016

Journal Articles

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Martino Introna, MD, Elisa Gotti, BA, Michela Bonzi, BA, Josee Golay, PhDBA, Alessandra Algarotti, MD, Caterina Micò, MD, Anna Grassi, MD, Cristina Boschini, Maria Luisa Ferrari, BSc, Irene Cavattoni, MD, Ettore Biagi, MD, Adriana Balduzzi, Sr., MD, Attilio Rovelli, MD, Paolo Perseghin, MD, Giuseppe Gaipa, PhD, Andrea Biondi, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3160.

https://doi.org/10.1182/blood.V126.23.3160.3160

Published: 2015

Journal Articles

Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab

Josée Golay, PhD, Fabio Da Roit, BSc, Luca Bologna, BSc, Claudia Ferrara Koller, PhD, Jeanette H. W. Leusen, PhD, Alessandro Rambaldi, MD, Christian Klein, PhD, Martino Introna, MD

Blood (2013) 122 (21): 4419.

https://doi.org/10.1182/blood.V122.21.4419.4419

Published: 2013

Journal Articles

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Josée Golay, PhD, Anna D’amico, PhD, Gianmaria Borleri, Maria Chiara Finazzi, MD, Giulia Quaresmini, MD, Martino Introna, MD, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 3272.

https://doi.org/10.1182/blood.V122.21.3272.3272

Published: 2013

Journal Articles

Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients

Blood (2012) 120 (21): 743.

https://doi.org/10.1182/blood.V120.21.743.743

Published: 2012

Journal Articles

A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results

Martino Introna, MD, Alessandra Algarotti, MD, Caterina Micò, MD, Anna Grassi, MD, Alice Pievani, PhD, Gianmaria Borleri, Josée Golay, PhD, Irene Cavattoni, MD, Sergio Cortelazzo, MD, Alessandro Rambaldi

Blood (2011) 118 (21): 657.

https://doi.org/10.1182/blood.V118.21.657.657

Published: 2011

Journal Articles

Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD

Erica Dander, PhD, Giovanna Lucchini, MD, Paola Vinci, Martino Introna, MD, Sonia Bonanomi, MD, Adriana Balduzzi, MD, Giuseppe Gaipa, PhD, Paolo Perseghin, MD, Francesca Masciocchi, Chiara Capelli, PhD, Josée Golay, PhD, Alessandra Algarotti, MD, Alessandro Rambaldi, MD, Attilio Rovelli, MD, Andrea Biondi, MD, Ettore Biagi, MD, Giovanna D'Amico, PhD

Blood (2010) 116 (21): 2306.

https://doi.org/10.1182/blood.V116.21.2306.2306

Published: 2010

Journal Articles

The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2 V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS

Ariel Amaru, MD, Katia Todoerti, PhD, Anna Pellicioli, Luca Donadoni, Giacomo Tuana, Olga Pedrini, Guido Finazzi, MD, Antonino Neri, MD, Gianluca Fossati, Alessandro Rambaldi, MD, Martino Introna, MD, Luigia Lombardi, Josée Golay, PhD

Blood (2010) 116 (21): 797.

https://doi.org/10.1182/blood.V116.21.797.797

Published: 2010

Journal Articles

Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies

Alice Pievani, PhD, Camilla Belussi, Christian Klein, PhD, Alessandro Rambaldi, MD, Josée Golay, Martino Introna, MD

Blood (2010) 116 (21): 4285.

https://doi.org/10.1182/blood.V116.21.4285.4285

Published: 2010

Journal Articles

Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.

Alice Pievani, Gianmaria Borleri, Camilla Belussi, Alessandro Rambaldi, Josee Golay, Martino Introna, MD

Blood (2009) 114 (22): 3024.

https://doi.org/10.1182/blood.V114.22.3024.3024

Published: 2009

Journal Articles

Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays.

Josee Golay, Luca Bologna, Elisa Gotti, Alessandro Rambaldi, Renato Bassan, Martino Introna, MD

Blood (2009) 114 (22): 3445.

https://doi.org/10.1182/blood.V114.22.3445.3445

Published: 2009

Journal Articles

IL-10 Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab.

Josee Golay, PhD, Marzia Leidi, Elisa Gotti, Giuseppe Palumbo, Martino Introna, MD

Blood (2008) 112 (11): 1582.

https://doi.org/10.1182/blood.V112.11.1582.1582

Published: 2008

Journal Articles

Selective Targeting of the JAK2 V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.

Vittoria Guerini, PhD, Valentina Barbui, PhD, Orietta Spinelli, PhD, Anna Salvi, Chiara Dellacasa, MD, Martino Introna, MD, Tiziano Barbui, MD, Josée Golay, PhD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 555.

https://doi.org/10.1182/blood.V110.11.555.555

Published: 2007

Journal Articles

Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.

Josee Golay, PhD, Marzia Leidi, BSc, Giuseppe A. Palumbo, MD, Martino Introna, MD

Blood (2006) 108 (11): 2507.

https://doi.org/10.1182/blood.V108.11.2507.2507

Published: 2006

Journal Articles

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Martino Introna, MD, Gianmaria Borleri, Elena Conti, Anna M. Barbui, MD, Raewyn Broady, BSc, Erica Dander, BSc, Giuseppe Gaipa, BSc, Giovanna D’Amico, BSc, Ettore Biagi, MD, Matteo Parma, MD, Enrico Pogliani, MD, Orietta Spinelli, BSc, Donatella Baronciani, MD, Anna Grassi, MD, Josee Golay, PhD, Tiziano Barbui, MD, Andrea Biondi, MD, Alessandro Rambaldi, MD

Blood (2006) 108 (11): 3698.

https://doi.org/10.1182/blood.V108.11.3698.3698

Published: 2006

NARROW

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients

A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results

Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD

The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2 V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS

Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies

Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.

Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MAbs Rituximab and Campath-1H in Whole Blood Assays.

IL-10 Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab.

Selective Targeting of the JAK2 V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.

Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only